ADMA Biologics, Inc.
ADMA
$20.68
$1.045.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 734.15% | 1,299.42% | 603.25% | 362.28% | -44.26% |
| Total Depreciation and Amortization | -7.82% | -7.27% | -2.43% | 3.98% | 8.91% |
| Total Amortization of Deferred Charges | -68.62% | -65.05% | -66.96% | -48.16% | 41.32% |
| Total Other Non-Cash Items | -369.04% | 14.79% | 9.31% | 2.70% | 1,088.47% |
| Change in Net Operating Assets | 280.77% | -520.20% | 267.58% | -95.73% | 100,211.11% |
| Cash from Operations | 185.37% | 108.83% | 853.36% | 84.94% | 338.47% |
| Capital Expenditure | -130.33% | -39.50% | -136.93% | -20.67% | 68.07% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.33% | -- | -- | -- | -- |
| Cash from Investing | -95.45% | -45.05% | -171.22% | -21.44% | 62.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 81.08% | -- | -- | -- | -1,822,716.09% |
| Issuance of Common Stock | 5,437.50% | 812.02% | -29.87% | -- | -99.99% |
| Repurchase of Common Stock | -88.86% | -456.73% | -206.64% | -286.88% | 83.51% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 94.53% | -- | -- | -- | -15,076,900.00% |
| Cash from Financing | 20.44% | -6,221.88% | -250.83% | -122.62% | -162.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 172.09% | -113.20% | 741.44% | 65.20% | -144.18% |